Patrys Limited
AASX:PAB0.03
AUD
0.00
(0.00%)
ISIN
AU000000PAB9
Return %
Stock
S&P 500
1Y
-6.67
14.20
3Y
-66.06
81.12
5Y
-93.18
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Samantha South
- Full Time Employees
- 15
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 168 Stirling Highway Nedlands WA Australia 6009
- IPO Date
- Jun 18, 2007
- Website
- patrys.com
- Similar Companies
- Business
- Patrys Limited Patrys Limited (ASX:PAB) develops novel antibody technologies targeting cancer and NETosis-driven inflammatory diseases through its proprietary deoxymab platform of cell-penetrating antibodies; key assets include PAT-DX1 (Deoxymab 3E10), a lead candidate for primary and secondary brain cancers, metastases, and combination therapies with DNA-damaging agents such as radiation and chemotherapy; and PAT-DX3, a full-sized antibody variant with distinct tissue distribution and pharmacokinetic properties optimized for enhanced therapeutic delivery. The company, founded in 2006 and headquartered in Melbourne, Australia, at Suite 2, Level 11, 385 Bourke Street, operates primarily in the biotechnology sector with a focus on oncology and immunology, leveraging an exclusive worldwide license from Yale University secured in 2016 for deoxymab applications; it maintains a wholly-owned subsidiary, Nucleus Therapeutics Pty Ltd, and pursues preclinical and clinical advancement across Australia and the United States. Recent developments encompass receipt of an R&D tax incentive refund of $1.285 million by Nucleus Therapeutics in December 2024; completion of a non-renounceable pro-rata entitlement offer raising up to $1.77 million; successful GMP production of PAT-DX1 by its contract development and manufacturing organization in early 2024 ahead of first-in-human clinical studies; and an Australian patent grant for the Deoxymab platform conjugated to nanoparticles for targeted anti-cancer drug delivery, alongside preclinical data demonstrating PAT-DX1-NP's ability to cross the blood-brain barrier for triple-negative breast cancer brain metastases.